On Friday, Following Stocks were among the “Top 100 Gainers” of U.S. Stock Market: Novavax, Inc. (NASDAQ:NVAX), Qunar Cayman Islands Limited (NASDAQ:QUNR), BG Medicine, Inc. (NASDAQ:BGMD), Cavium, Inc. (NASDAQ:CAVM)

Novavax, Inc. (NASDAQ:NVAX), with shares gained 8.44%, closed at $8.22.

Qunar Cayman Islands Limited (NASDAQ:QUNR), with shares jumped 8.43%, settled at $41.78, hitting new 52-week high of $41.94 .

BG Medicine, Inc. (NASDAQ:BGMD), with shares climbed 6.99%, and closed at $0.995.

Cavium, Inc. (NASDAQ:CAVM), surged 7.60%, and closed at $71.94.

Latest NEWS regarding these Stocks are depicted underneath:

Novavax, Inc. (NASDAQ:NVAX)

Novavax, Inc. (NVAX), declared Gale Smith, Ph.D., Vice President, Vaccine Development, will present, “Recombinant EBOV/Makona Glycoprotein (GP) Nanoparticle Vaccine Produced in Sf9 Insect Cells,” at the 7th International Symposium on Filoviruses, Saturday, March 28, 2015 at 10:15 a.m. at the Washington Marriott Metro Center in Washington, D.C.

As part of his talk, Dr. Smith will present new data from a second non-human primate (NHP) study which was conducted by the National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of Microbiology and Infectious Diseases (NIH-NIAID-DMID). In that study, animals received two injections of a 5ug dose of Novavax’ Ebola GP Vaccine together with its proprietary Matrix-M adjuvant and were then challenged with a lethal dose of the Ebola virus. Similar to the previous NHP study, the challenge was lethal for the control animals, whereas the animals immunized with Novavax’ EBOV GP Vaccine remain healthy 18 days post challenge.

Novavax is presently conducting a Phase 1 clinical trial of its Ebola GP Vaccine in healthy subjects. It anticipates top-line data from this trial in mid-2015.

Novavax, Inc., a clinical-stage vaccine corporation, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The corporation produces its vaccines using its proprietary recombinant nanoparticle vaccine technology.

Qunar Cayman Islands Limited (NASDAQ:QUNR)

Formerly on March 20, Qunar Cayman Islands Limited (QUNR), declared that the corporation’s CEO, Chenchao (CC) Zhuang, has been named among the World Economic Forum’s Young Global Leaders (YGLs) for 2015. Mr. Zhuang was one of 187 business leaders, chosen from a global pool of 2000 entrepreneurs under the age of 40, recognized by the WEF for their outstanding professional accomplishments and tangible contributions to their countries and industries.

The World Economic Forum lists 11 heads of state and government, 10 heads of Fortune 500 companies, 15 UN Goodwill Ambassadors, six Guinness World Record holders, four Oscar winners, three Olympic gold medalists, two Nobel Prize winners and an astronaut among its current and former YGLs.

Qunar Cayman Islands Limited operates online travel commerce platform for travel service providers (TSPs) and display advertisers in the People’s Republic of China.

BG Medicine, Inc. (NASDAQ:BGMD)

BG Medicine, Inc. (BGMD), declared the publication of a landmark study, in the Journal of the American College of Cardiology, reporting clinical outcome results of the BioImage Study. The BioImage Study, sponsored by BG Medicine in partnership with pharmaceutical and healthcare companies Abbott, AbbVie, AstraZeneca, Merck, Philips, and Takeda, is a large, prospective study of cardiovascular disease in asymptomatic men and women in the United States. The BioImage Study recruited 7,687 men and women above the age of 55 and monitored them for about 3 years for the occurrence of major cardiovascular events such as heart attack, stroke, and death due to cardiovascular causes.

The recent publication appeared in the March 24, 2015 issue of the Journal of the American College of Cardiology, the flagship journal of the American College of Cardiology. The lead authors, from the Mount Sinai Medical Center in New York, stated the occurrence of 216 first major adverse cardiovascular events in BioImage Study participants during the follow-up period. Of these, the authors found that 184 events, or over 85% of all events, occurred in individuals who were believed at the outset of the study to be at low or intermediate cardiovascular risk, as determined by conventional, office-based Framingham Heart Study risk assessment.

The authors report that a noteworthy proportion of men and women, nearly 60%, showed evidence of accumulated plaque in the major arteries that supply blood to the heart and to the brain, indicating potential undetected vascular disease. Participants in the BioImage Study underwent extensive medical imaging to detect such plaques, counting experimental ultrasound measurement of the arteries in the neck, and advanced X-ray-based computed tomography scans of the heart.

BG Medicine, Inc., a diagnostics corporation, develops and commercializes novel cardiovascular diagnostic tests to address unmet medical needs in the United States. The corporation offers BGM Galectin-3 test, a novel assay for measuring galectin-3 levels in blood plasma or serum for use as an aid in assessing the prognosis of patients diagnosed with heart failure; and CardioSCORE test, which is designed to identify individuals at high risk for cardiovascular events, such as heart attack and stroke.

Cavium, Inc. (NASDAQ:CAVM)

Formerly on March 16, Cavium, Inc. (CAVM), declared it has added support for NVIDIA® Tesla® GPU accelerators in its ThunderX ARM® processor family.

The ThunderX product family is Cavium’s 64-bit ARMv8 server processor for next generation data center and cloud applications. The ThunderX family integrates up to 48 high performance ARMv8-A custom cores, single and dual socket configurations, high memory bandwidth, large memory capacity, integrated hardware accelerators, integrated feature rich high bandwidth network and storage IO, fully virtualized core and IO, and scalable high bandwidth, low latency Ethernet fabric ThunderX enables best in class performance per dollar and performance per watt.

The NVIDIA Tesla Accelerated Computing Platform is the leading platform for accelerating data analytics, deep learning and scientific computing. By adding support for Tesla GPUs, Cavium will further enhance the performance and compute efficiency that ThunderX delivers to the server market.

Many key application and market segments will benefit directly from this combination, counting:

• High performance computing (HPC) workloads that require high levels of double precision floating point compute performance. These compute workloads also require high data throughput and compute density which ThunderX delivers in both 48 core single socket configurations and 96 core dual socket configurations.
• Data analytics workloads that require real-time results to drive critical business decisions. The integration of compute and storage that ThunderX delivers in an optimized SoC (System on Chip) is critical to providing the complete system solution required for leading data scientists.

Cavium, Inc. designs, develops, and markets semiconductor processors for intelligent and secure networks in United States and internationally. It offers integrated semiconductor processors for wired and wireless networking, communications, storage, cloud, wireless, security, video, and connected home and office applications.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.